Navigation Links
It takes a community to address cancer disparities among underserved minority populations
Date:11/30/2007

he first-ever assessment of cancer awareness among members of the Navajo Nation, researchers at the University of Arizona Cancer Center have determined that cancer education efforts have not reached the tribe, particularly with regard to colorectal cancer (CRC).

With funding from the National Cancer Institute, the study leader, Priscilla Sanderson, Ph.D., a post-doctoral fellow at the University of Arizona Cancer Center and herself a Navajo, has undertaken an extensive review of attitudes toward cancer among the nearly 200,000 members of the Navajo Nation who live in the Navajo Reservation, an area of land that occupies most of northeastern Arizona as well as parts of New Mexico and Utah.

To establish a baseline of colorectal cancer awareness, Sanderson surveyed Navajo at tribal fairs and health centers and held focus groups of tribal elders. Results of our studies show that awareness and interest in colorectal rectal cancer screening among the Navajo Nation is present, Sanderson said.

However, the proportion of those reporting undergoing CRC screening is much lower than the national average, and that may have a direct effect upon cancer survival.

Colorectal cancer is one of the most common forms of cancer in the United States, with over 150,000 new cases of CRC each year. Since CRC is most common in older adults, doctors generally recommend that every man and woman be regularly screened after age 50. If caught early, CRC has a 50 percent five-year survival rate. According to Sanderson, hard data on CRC incidence among Navajo is not conclusive, but rates are actually thought to be somewhat lower than in other ethnic groups in the United States.

Part of the problem involves public health resources, but there is a definite cultural component that has inadvertently stood in the way of cancer awareness, Sanderson said.

One example given by Sanderson is that many Navajo especially the older members of the tri
'/>"/>

Contact: Greg Lester
greg.lester@aacr.org
267-646-0554
American Association for Cancer Research
Source:Eurekalert

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Free will takes flight: how our brains respond to an approaching menace
2. New AHIP Report Takes a Ten Year Look at the Unintended Consequences of State Efforts to Change the Insurance Market
3. Sun Safety Outreach to Families Takes Flight at the Plano Hot Air Balloon Festival
4. Small Army Takes on Cure for Diabetes and New Approach to Ending World Poverty with Addition of Non-Profit Accounts
5. Small Town Doctor Takes on Giants in Consumer Healthcare
6. Help is Available for Smokers Who Want to Quit as Minnesotas Smoke-Free Law Takes Effect Oct. 1
7. Growing Healthy with School Gardens Takes Root in Los Angeles Saturday
8. Randy Jackson Takes Aim at Diabetes
9. New Hampshire: 1st in the Nation Primary State Takes a Stand on E-Prescribing
10. Blood test takes step toward predicting Alzheimers risk, Stanford researchers find
11. Morrison Takes Aim at Underage Drinking in New Radio Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Ameritox(R) Appoints Jay B. Zimmerman as Chief Operating Officer 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Bayer Consumer Care Voluntarily Recalls One Lot of Combination Package of Alka-Seltzer Plus(R) Day & Night Cold Formula Liquid Gels 2New Swine Flu Strain Found in Brazil 3A Report 49266 1New Swine Flu Strain Found in Brazil 3A Report 49266 2New Swine Flu Strain Found in Brazil 3A Report 49266 3New Swine Flu Strain Found in Brazil 3A Report 49266 4New Swine Flu Strain Found in Brazil 3A Report 49266 5New Swine Flu Strain Found in Brazil 3A Report 49266 6New Swine Flu Strain Found in Brazil 3A Report 49266 7New Swine Flu Strain Found in Brazil 3A Report 49266 8New Swine Flu Strain Found in Brazil 3A Report 49266 9New Swine Flu Strain Found in Brazil 3A Report 49266 10New Swine Flu Strain Found in Brazil 3A Report 49266 11New Swine Flu Strain Found in Brazil 3A Report 49266 12Fathers 26apos 3B Hearing Affects Family Function and Fiscal Health 49263 1Fathers 26apos 3B Hearing Affects Family Function and Fiscal Health 49263 2Fathers 26apos 3B Hearing Affects Family Function and Fiscal Health 49263 3Fathers 26apos 3B Hearing Affects Family Function and Fiscal Health 49263 4MedNet Solutions Unveils New Naming and Functionality for its Flagship EDC eClinical Offering 12678 1MedNet Solutions Unveils New Naming and Functionality for its Flagship EDC eClinical Offering 12678 2